SGLT2 inhibitors reduce progression of kidney damage in diabetes (Tuttle et al., 2021) and recently this effect has been shown in non-diabetic kidney disease as well, possibly by reducing proximal tubule stress (Almaimani et al., 2021). This evidence concerns the gene SLC5A2 and diabetic kidney disease.